Abstract
Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.
Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.
Current Pharmaceutical Design
Title:Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?
Volume: 18 Issue: 32
Author(s): Amir Englund, James M. Stone and Paul D. Morrison
Affiliation:
Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.
Abstract: Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.
Export Options
About this article
Cite this article as:
Englund Amir, M. Stone James and D. Morrison Paul, Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884618
DOI https://dx.doi.org/10.2174/138161212802884618 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
- Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Creating Change: How Knowledge Translates into Action for Protecting Babies from Sudden Infant Death?
Current Pediatric Reviews Alzheimer’s Drug Discovery Maze: A Snap View of the Past Decade’s Diverse Pharmacological Targets for the Disorder
Mini-Reviews in Medicinal Chemistry Editorial:
Neuroscience and Biomedical Engineering (Discontinued) The Neurobiological Bases for the Pharmacotherapy of Nicotine Addiction
Current Pharmaceutical Design Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry Enhanced Nitinol Properties for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Recent Development of G-Quadruplex Probes for Cellular Imaging
Current Topics in Medicinal Chemistry Synaptic Plasticity in PTSD and associated Comorbidities: The Function and Mechanism for Diagnostics and Therapy
Current Pharmaceutical Design Advances in Antioxidant Potential of Natural Alkaloids
Current Bioactive Compounds γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Current Pharmaceutical Design A Novel Non-invasive Effective Method for Potential Treatment of Degenerative Disc Disease: A Hypothesis
Central Nervous System Agents in Medicinal Chemistry Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Chemoinformatics in Multi-target Drug Discovery for Anti-cancer Therapy: In Silico Design of Potent and Versatile Anti-brain Tumor Agents
Anti-Cancer Agents in Medicinal Chemistry A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment
Current Drug Abuse Reviews The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology HDL Apolipoprotein-Related Peptides in the Treatment of Atherosclerosis and other Inflammatory Disorders
Current Pharmaceutical Design